Navigation Links
Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting
Date:5/15/2013

al uses of such tool. The forward-looking statements are usually (but not always) identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning.  Actual results could differ materially from the expectations contained in forward-looking statements as a result of risks and uncertainties including clinical trial enrollment and results, regulatory approval requirements, unexpected expenditures and costs, unexpected results or delays in development and regulatory review, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 8, 2013. Halozyme does not undertake to update these forward-looking statements.

References
1. American Cancer Society, Cancer Facts & Figures 2013. Atlanta: American Cancer Society; 2013
2. Pancreatic Cancer, American Cancer Society, http://www.cancer.org/cancer/pancreaticcancer/detailedguide/pancreatic-cancer-key-statistics  Accessed April 18, 2013

 

Investor Contact:
Kurt Gustafson
Halozyme Therapeutics
858-704-8272
ir@halozyme.com

Media Contact:
Nurha Hindi
Hill+Knowlton Strategies
310-633-9434
Nurha.Hindi@hkstrategies.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
2. Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
3. Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
4. Halozyme to Host Second Quarter Financial Results Conference Call
5. Halozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference Call
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
7. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
8. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... TEL AVIV, Israel , May 5, 2015 ... that the Company was approved to continue trading ... companies. OTCQB Marketplace allows for ... an electronic broker-dealers. Investors can have real-time quotes ... The OTCQB Marketplace includes ...
(Date:5/5/2015)... , May 5, 2015  A group of biotechnology ... the Coma Research Institute, a non-profit organization dedicated to ... families suffering from disorders of consciousness.  ... http://photos.prnewswire.com/prnh/20150504/213779LOGO   ... consciousness, in which no voluntary actions can be initiated ...
(Date:5/5/2015)... Calif. , May 5, 2015 CytomX, ... of cancer, today announced that Sean McCarthy , ... Credit Suisse Antibody Day in New York ... 6. Dr. McCarthy will present an overview of CytomX,s ... Probody drug conjugate programs. About CytomX Therapeutics ...
(Date:5/5/2015)... -- Indianapolis-based medical device manufacturer NICO Corporation is seeing ... including the BrainPath® and Myriad™ technologies offering a ... and then removing affected tissue. More than 1,600 ... institutions throughout the United States ... 12 abstracts, three peer-reviewed publications, and seven presentations ...
Breaking Biology Technology:Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 4Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 5NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 2NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 3
... Drug Offers Potential Treatment ... to Americans Suffering from IBS-C, BETHESDA, Md., Sept. 17 ... the supplemental,New Drug Application (sNDA) for lubiprostone (8 mcg, oral ... with,constipation (IBS-C) has been accepted for review by the U.S. ...
... 17 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ) ... President, will present an overview of the Company,s ... Annual Investment Conference,in San Francisco. Dr. Henderson,s presentation ... am PT. Dr. Henderson,s presentation will be ...
... Tissue Provides Building-Block Cells for Muscle, Bone, ... ... BioLife Solutions,Inc. (OTC Bulletin Board: BLFS), a leading developer ... tissues, and organs, today announced that privately held Tissue,Regeneration Therapeutics ...
Cached Biology Technology:FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 2FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 3FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 4FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 5Keryx Biopharmaceuticals to Present at Bank of America Investment Conference 2BioLife Solutions' CryoStor(TM) Adopted by Tissue Regeneration Therapeutics for Preservation Protocol for New, Non-Embryonic Source of Stem Cells 2BioLife Solutions' CryoStor(TM) Adopted by Tissue Regeneration Therapeutics for Preservation Protocol for New, Non-Embryonic Source of Stem Cells 3
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications Corp. ... global provider of Software Defined Network Architecture (ET Software ... total revenue of approximately $20.4 million for the year ... $19.5 million for the year ended December 31, 2013. ... the Company had completed its multi-year transition away from ...
(Date:3/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ... Iris Recognition Market 2015-2019" report to their offering. ... market to grow at a CAGR of 23.5 percent ... the present scenario and the growth prospects of the ... calculate the market size, the report considers the revenue ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... doesn,t bed down with theatre, much less mate with ... explored in the recent production Heuschrecken [The Locusts] developed ... asks Arizona State University,s Manfred Laubichler and Gitta Honegger ... of the journal Science . "Scientists have ...
... WASHINGTON, Jan. 28, 2010 The U.S. Department ... the release of new satellite images depicting agricultural land ... crop year. The images, referred to as cropland data ... rotation patterns, land use changes, water resources and carbon ...
... The Genetics Society of America (GSA) is pleased ... distinguished service to the field of genetics. These ... the genetics community. The individuals who receive these ... recognition of the exceptional value of their work to ...
Cached Biology News:Scientists and cast of thousands swarm stage in Europe 2Scientists and cast of thousands swarm stage in Europe 3The Genetics Society of America announces its 2010 award recipients 2The Genetics Society of America announces its 2010 award recipients 3
Edited by D. Patel (1994) Comprehensive data on gel electrophoresis of proteins, nucleic acids, nucleoproteins and carbohydrates....
...
... Silver Staining Kit, 1. Select from ... and peptides on denaturing, native, and ... reproducibility with precast gels, buffer strips, ... to that of radioisotopes with ready-to-use ...
Human HAPLN1 MAb (Clone 316119) Protein Family: Hyaluronan (HA) & HA Binding Proteins, Proteoglycan Regulators...
Biology Products: